Vitalis Therapeutics Inc. — Every draw against the $26,040,000 contingency reserve for the VitaFlow (VTX-401) program: what it funded, who approved it, and what the rejected alternative was. Status at 15 October 2026.
1. Purpose & Rules
The contingency reserve for the VitaFlow (VTX-401) program is $26,040,000, 12% of the $217,000,000 base program. This register records every draw against it.
- The reserve sits outside every stage tranche. It is not inside any of the five tranches recorded in the Program Budget, which is precisely what makes a draw visible rather than absorbed into stage spend.
- Draws are approved individually by the Development Committee, against a named risk or an approved change. There is no lump-sum top-up to a stage.
- Functional leads cannot draw on it. It is not a stage-level buffer and does not appear in any functional budget.
- Every draw records the rejected alternative. See §3.
Draw Authority
Who may approve a draw depends on its size, and what evidence they must see depends on the same thing.
| Amount | Approver | Recording | Evidence required |
|---|---|---|---|
| Up to $500,000 | Program Director | Notified to the Committee at the next checkpoint. | Operational recovery within an authorized stage. |
| $500,001 – $2,500,000 | Committee Chair with CFO concurrence | Minuted at the next Committee meeting. | Requires a written statement of the rejected alternative. |
| Above $2,500,000 | Full Development Committee | Formal decision, recorded in the register. | Requires alternatives assessment and an impact statement on the remaining reserve. |
| Any draw that would exhaust the reserve | Board | Escalated. The reserve sits inside the ceiling. | Exhausting contingency is a ceiling matter, not a contingency matter. |
The threshold is set where it is because it is small enough that a series of Chair-approved draws cannot quietly consume the reserve, and large enough to cover the operational recoveries that actually arise.
2. Register
| Ref | Draw | Against | Type | Approved | Amount |
|---|---|---|---|---|---|
| CD-01 | Cardiovascular outcomes sub-study | CR-02 | Approved change | 20 Apr 2026 | $7,200,000 |
| CD-02 | CMC analytical method transfer recovery | I-02 | Materialised issue | 24 Mar 2026 | $1,850,000 |
| Total drawn | $9,050,000 | ||||
| Reserve remaining | $16,990,000 |
35% of the reserve is consumed with the largest cost pool — Phase 3, at $109,100,000 — still running. That is a position worth watching rather than an alarm, and the distinction turns on what the two draws actually are.
3. How the Reserve Was Sized
12% of base is a choice, not a convention, and the number encodes a judgment about what kind of program this is.
| Consideration | Effect on the percentage |
|---|---|
| Stage of the program at authorization | Late-phase programs carry less uncertainty per dollar than early ones. Published practice puts 10–15% on late-phase work and 15–20% on early phase. |
| Concentration of spend | 58% of base sits in one stage. A reserve has to be adequate against the stage that dominates, not against the average stage. |
| Proportion of cost that is external | 83%. Contracted work varies less than internal effort, which argues for a lower reserve — but change orders are the mechanism by which it varies, and they are not free. |
| Regulatory dependency | An agency expectation can add scope at any time. CR-02 is exactly that case, and it alone consumed 28% of the reserve. |
4. Outside the Reserve
Naming the exclusions is what stops a reserve from becoming a general-purpose fund.
- Ordinary cost variance inside a stage. A work package running over is managed within the tranche, not topped up from reserve.
- Scope the Committee declined. A rejected change does not return as a contingency request.
- Anything beyond the authorized ceiling. The reserve is inside $243,040,000, not additional to it. Exhausting it does not create headroom — it escalates to the Board.
- Stage 5 scope not yet released. Contingency cannot be used to start work a gate has not authorized.
- Commercial launch investment. Pre-launch commercial spend is a separate authorization and does not draw here.
3. Why Each Entry Records a Rejected Alternative
Most contingency registers record an amount, a date and a one-line reason. That is enough to audit whether the money was authorized, and not nearly enough to judge whether it was spent well.
The question a reader has eighteen months later is not “was this approved?” — it plainly was, or it would not be in the register. The question is what else could have been done, and was the choice defensible on what was known at the time? That information exists only at the moment of decision. If it is not written down then, it is gone, and the draw becomes unreviewable: an amount with a justification attached and no way to test it.
4. Draw Records
CD-01 — Cardiovascular outcomes sub-study
| Field | Record |
|---|---|
| Amount | $7,200,000 (28% of reserve) |
| Drawn against | CR-02 — approved change |
| Approved | 20 April 2026 |
| Decided by | Development Committee |
Rationale
Added on agency expectation recorded at the End-of-Phase-2 meeting. Carried as a change with a named draw rather than absorbed into the Phase 3 estimate, so that later variance analysis attributes it to a governance decision rather than to poor estimation.
Alternative considered and rejected
Decline the sub-study and accept the likelihood of a post-marketing requirement negotiated during review. Rejected: a commitment negotiated from weakness during review is worse than a study designed on the program's own terms.
CD-02 — CMC analytical method transfer recovery
| Field | Record |
|---|---|
| Amount | $1,850,000 (7% of reserve) |
| Drawn against | I-02 — materialised issue |
| Approved | 24 March 2026 |
| Decided by | Development Committee |
Rationale
Method transfer to Aldergate failed first-pass acceptance on two of three methods. Funds an embedded CMC team on site and a re-qualification campaign.
Alternative considered and rejected
Manage within the Stage 4 tranche. Rejected: it would have absorbed a recovery cost into stage spend and hidden the only draw in this program that carries a lesson.
5. Reading the Two Draws Together
They consume the reserve at similar orders of magnitude — $7,200,000 and $1,850,000 — and they mean entirely different things.
| CD-01 — CR-02 | CD-02 — I-02 | |
|---|---|---|
| Origin | A choice the program made | Something that went wrong |
| Foreseen? | Yes — arose from a known agency expectation | No — was not on any risk register |
| What it buys | Scope: a study designed on the program's terms | Recovery: getting back to where the plan assumed the program already was |
| Lesson | None. The mechanism worked as intended. | Technical transfer between organizations is systematically under-registered |
7. Forecast
$16,990,000 remains against one pivotal read-out, one filing, a review period and a pre-approval inspection.
| Remaining exposure | Reserve implication |
|---|---|
| PPQ campaign failure | Three consecutive batches. A failure costs the sequence plus investigation — the largest single plausible draw remaining. |
| Pre-approval inspection finding | R-07, rated Low. Remediation cost depends entirely on what is found. |
| Agency information requests during review | Usually absorbed in regulatory effort; a request for new analysis is not. |
| Enrolment recovery beyond the current plan | Additional sites are the recovery lever, and sites cost money. |
| Phase 3 read-out | No reserve implication. A failed pivotal does not draw contingency — it ends the program. |
That is the correct reading of R-01 and R-02, and it means the reserve position — while worth watching — is not the thing to watch most closely. The largest uncertainty in this program has no financial mitigation at all.
Requests Declined
A register that records only approvals is a record of spending, not a record of control.
| Date | Request | Amount | Reason declined |
|---|---|---|---|
| 2027-04-11 | Additional biomarker sub-study | $3,200,000 | Scientifically interesting, not required for the filing and not in the TPP. Contingency is not a mechanism for funding scope the gate did not authorize. |
| 2028-02-27 | Accelerated EU dossier preparation | $2,400,000 | EU filing is explicitly out of scope (Charter §4). A declined scope item does not return as a contingency request. |
| 2029-05-09 | Additional launch market research | $900,000 | Commercial launch investment sits under a separate authorization. Declined on jurisdiction, not on merit. |
Total declined: $6,500,000 — more than half again the $1,850,000 drawn for I-02.
The biomarker sub-study was declined because contingency is not a mechanism for funding scope the gate did not authorize. The EU dossier was declined because a scope item the Charter explicitly excluded does not return through a side door. The market research was declined on jurisdiction, not merit — commercial launch investment has its own authorization and this reserve is not it.
Each of the three was, in isolation, a reasonable thing to want. A reserve that funds reasonable things is a general-purpose budget with a more respectable name, and it will not be there when an agency asks for a cardiovascular outcomes sub-study.
6. Remaining Reserve
| Measure | Amount |
|---|---|
| Reserve at authorization | $26,040,000 |
| Drawn to date | $9,050,000 |
| Remaining | $16,990,000 |
| Remaining as % of unspent base | 14.6% |
$16,990,000 remains against what is left of the program: completion of both pivotal trials and the cardiovascular sub-study, database lock, the NDA submission, the review period, and the pre-approval inspection.
Expressed against unspent base rather than against the original ceiling, the reserve is 14.6% — below the 12% the program was authorized with. That is the honest way to read it. A reserve percentage quoted against the original base flatters a program that has spent half its money, because the risk that remains is not proportional to the money already spent.